Drugs / Trastuzumab duocarmazine
Trastuzumab duocarmazine
also known as
SYD985 · [vic-]trastuzumab duocarmazine · SYD985: (vic-)trastuzumab duocarmazine · T-Duo · Trastuzumab duocarmazina
Other / unclassified targets ERBB2
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04602117 | Jul → Nov 2021 | HER2 positive breast carcinoma, carcinoid tumor, endometrium neoplasm, gastroesophageal adenocarcinoma +6 | QuantumLeap Healthcare Collaborative | Withdrawn | No outcome recorded |
| Phase 1 | NCT04235101 | Jun 2020 → Apr 2023 | cancer | Byondis B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02277717 | Oct 2014 → Jan 2019 | cancer | Byondis B.V. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04205630 | May 2020 → Jan 2023 | endometrial cancer | Byondis B.V. | Completed | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03262935 | Dec 2017 → Mar 2021 | breast cancer | Byondis B.V. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04983238 Background | Jan 2022 → Apr 2023 | breast cancer | Byondis B.V. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab duocarmazine | “Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin.” PMID 31257177 ↗ Jun 2019 |
| Known as | [vic-]trastuzumab duocarmazine | “SYD985 ([vic-]trastuzumab duocarmazine)” NCT01042379 ↗ |
| Known as | SYD985 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01042379 ↗ |
| Known as | SYD985: (vic-)trastuzumab duocarmazine | “SYD985: (vic-)trastuzumab duocarmazine” NCT04983238 ↗ |
| Known as | T-Duo | “Trastuzumab duocarmazine (T-Duo) is a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies of heavily...” PMID 39442070 ↗ Oct 2024 |
| Known as | Trastuzumab duocarmazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298178 ↗ |
| Action | Deplete | “subsequently kills the cancer cell.” NCT04235101 ↗ |
| Modality | Other / unclassified | “SYD985 is an antibody-drug conjugate” NCT04235101 ↗ |
| Route | Intravenous | “SYD985: 1.2 mg/kg IV” NCT01042379 ↗ |
| Target | ERBB2 | “HER2-targeted antibody-drug conjugate” PMID 39442070 ↗ Oct 2024 |